![Len Rosenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Len Rosenberg
Plus aucun poste en cours
Profil
Len Rosenberg is associated with Diasome Pharmaceuticals, Inc. as the founder.
He held the position of President, Chief Executive Officer & Director from 2013 to 2014.
Diasome Pharmaceuticals, Inc. was founded in 2004.
Anciens postes connus de Len Rosenberg
Sociétés | Poste | Fin |
---|---|---|
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Directeur Général | 09/01/2014 |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Health Technology |